Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10408077 | 0.89 | KMT2A (0.53) | ALDH1A1SMN1; SMN2TSHRHSD17B10KMT2A | |
| SCHEMBL14768684 | 0.80 | KDM4E (0.51) | ALDH1A1SMN1; SMN2TSHRHSD17B10KMT2A | |
| SCHEMBL23161511 | 0.79 | SMN1; SMN2 (0.56) | ALDH1A1SMN1; SMN2TSHRHSD17B10KMT2A | |
| SCHEMBL3042980 | 0.79 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2TSHRHSD17B10KMT2A | |
| SCHEMBL7490418 | 0.78 | SLC2A1 (0.44) | ALDH1A1SMN1; SMN2TSHRHSD17B10KMT2A | |
| SCHEMBL14485349 | 0.77 | ALDH1A1 (0.62) | ALDH1A1SMN1; SMN2KMT2AMEN1MAPT | |
| SCHEMBL1239113 | 0.77 | KEAP1 (0.57) | ALDH1A1SMN1; SMN2TSHRHSD17B10KMT2A | |
| SCHEMBL30851436 | 0.77 | KEAP1 (0.57) | ALDH1A1SMN1; SMN2TSHRHSD17B10KMT2A | |
| SCHEMBL6005480 | 0.77 | KEAP1 (0.57) | ALDH1A1SMN1; SMN2TSHRHSD17B10KMT2A | |
| SCHEMBL1361268 | 0.76 | ADRB1 (0.58) | ALDH1A1SMN1; SMN2TSHRKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023122778-A1 | PYRIDAZINONE DERIVATIVES USEFUL AS T CELL ACTIVATORS | GOSSAMER BIO SERVICES, INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023122778-A1 | PYRIDAZINONE DERIVATIVES USEFUL AS T CELL ACTIVATORS | GOSSAMER BIO SERVICES, INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| EP-2536697-B1 | NOVEL ANTIFUNGAL TRIAZOLE DERIVATIVES | DAE WOONG PHARMA (KR) | 2016-10-19 | — | — | EP | disclosed |
| US-8940768-B2 | Antifungal triazole derivatives | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2015-01-27 | — | — | US | disclosed |
| CN-101798302-B | Method and technology for synthesizing and producing antibiotic medicament namely 1-(o-fluorophenyl) dihydropyridone | MICURX SHANGHAI PHARMACEUTICAL INC | 2014-11-05 | — | — | CN | disclosed |
| EP-2536697-A2 | NOVEL ANTIFUNGAL TRIAZOLE DERIVATIVES | Daewoong Pharmaceutical Co., Ltd (KR) | 2012-12-26 | — | — | EP | disclosed |
| US-20120309771-A1 | NOVEL ANTIFUNGAL TRIAZOLE DERIVATIVES | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2012-12-06 | — | — | US | disclosed |
| US-20120214807-A1 | COMPOUNDS USEFUL AS ANTAGONISTS OF CCR2 | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| EP-2435426-A1 | BENZOXAZEPINES AS INHIBITORS OF PI3K/m TOR AND METHODS OF THEIR USE AND MANUFACTURE | Exelixis, Inc. (US) | 2012-04-04 | — | — | EP | disclosed |
| US-8067457-B2 | Compounds useful as antagonists of CCR2 | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| WO-2011099804-A2 | NOVEL ANTIFUNGAL TRIAZOLE DERIVATIVES | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2011-08-18 | — | — | WO | disclosed |
| WO-2010138487-A1 | BENZOXAZEPINES AS INHIBITORS OF PI3K/m TOR AND METHODS OF THEIR USE AND MANUFACTURE | EXELIXIS, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
| CN-101798302-A | Method and technology for synthesizing and producing antibiotic medicament namely 1-(o-fluorophenyl) dihydropyridone | MICURX SHANGHAI PHARMACEUTICAL INC | 2010-08-11 | — | — | CN | disclosed |
| US-20090197884-A1 | Compounds Useful as Antagonists of CCR2 | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-08-06 | — | — | US | disclosed |
| US-7304076-B2 | Neuropeptide Y Y5 receptor antagonists | SCHERING CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304076-B2 | Neuropeptide Y Y5 receptor antagonists | SCHERING CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| WO-2007053498-A1 | COMPOUNDS USEFUL AS ANTAGONISTS OF CCR2 | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214807-A1 | COMPOUNDS USEFUL AS ANTAGONISTS OF CCR2 | CCR2, CCR1, CXCR3 | ALDH1A1 1292/4885SMN1; SMN2 3742/4885TSHR 864/4885 |
| US-20120309771-A1 | NOVEL ANTIFUNGAL TRIAZOLE DERIVATIVES | ERG28, CYP51A1, DPM1 | ALDH1A1 2469/4885SMN1; SMN2 4216/4885TSHR 4253/4885 |
| US-20090197884-A1 | Compounds Useful as Antagonists of CCR2 | CCR2, CCR1, CXCR3 | ALDH1A1 1292/4885SMN1; SMN2 3742/4885TSHR 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.